Emergent Biosolutions (EBS)Director sold ~$63K

~$63K

Approx. value · 7,086 sh @ $8.87

72K

Holds after · shares reported

Traded

Aug 15, 2025

Filed

Aug 18, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 12, 2025InsiderDirector sold ~$68K of EBS shares in the open market
2. Aug 15, 2025 · this disclosureInsiderDirector sold ~$63K of EBS shares in the open market

What came next

1. Sep 5, 2025Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
2. Oct 29, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
3. Nov 7, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On November 7, 2025, Louis W. Sullivan, M.D., a director of Emergent BioSolutions Inc. (the “Company”), notified the Company of his intent to retire as a Class II board member effective November 14, 2025.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Emergent Biosolutions

For Emergent Biosolutions, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EBS page.

Other recent filings by Kathryn C Zoon, Director

• SEC Form 4 at Emergent Biosolutions (EBS)Mar 12, 2025

The full history of Kathryn C Zoon, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Emergent Biosolutions

• SEC Form 144Oct 7, 2026
• SEC Form 4Oct 7, 2026
• SEC Form 4Oct 5, 2026
• USAspending.gov award recordJun 4, 2026
• USAspending.gov award recordApr 28, 2026
• USAspending.gov award recordMar 4, 2026

Everything OQRO holds on this company is on its EBS page.